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Background: Hematopoiesis is a progressive process collectively controlled by an elaborate network of transcription
factors (TFs). Among these TFs, GATA2 has been implicated to be critical for regulating multiple steps of hematopoiesis
in mouse models. However, whether similar function of GATA2 is conserved in human hematopoiesis, especially during
early embryonic development stage, is largely unknown.
Results: To examine the role of GATA2 in human background, we generated homozygous GATA2 knockout human
embryonic stem cells (GATA2−/− hESCs) and analyzed their blood differentiation potential. Our results demonstrated
that GATA2−/− hESCs displayed attenuated generation of CD34+CD43+ hematopoietic progenitor cells (HPCs), due to
the impairment of endothelial to hematopoietic transition (EHT). Interestingly, GATA2−/− hESCs retained the potential
to generate erythroblasts and macrophages, but never granulocytes. We further identified that SPI1 downregulation
was partially responsible for the defects of GATA2−/− hESCs in generation of CD34+CD43+ HPCs and granulocytes.
Furthermore, we found that GATA2−/− hESCs restored the granulocyte potential in the presence of Notch signaling.
Conclusion: Our findings revealed the essential roles of GATA2 in EHT and granulocyte development through
regulating SPI1, and uncovered a role of Notch signaling in granulocyte generation during hematopoiesis modeled by
human ESCs.
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Hematopoiesis is a complex process that involves multiple
developmental processes, such as cellular proliferation,
differentiation, and survival. This process is accurately
controlled by the coordination of a set of transcription
factors and diverse signaling pathways [1–5]. GATA2
belongs to the transcriptional regulatory GATA protein
family and is broadly expressed in hematopoietic cells,* Correspondence: pan_guangjin@gibh.ac.cn
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article, unless otherwise stated.particularly in hematopoietic progenitors [6, 7]. The es-
sential function of GATA2 in genesis, differentiation, and
even trans-differentiation of hematopoietic stem/or pro-
genitor cells (HSCs or HPCs) has been extensively exam-
ined [8, 9]. A GATA2-deficient mouse exhibited severe
anemia and died at early stage of gestation due to a
reduced number of primitive erythroid cells and HPCs
[10], highlighting the essential role of GATA2 in early
hematopoiesis. Furthermore, GATA2 is also crucial in
maintaining the proliferation and normal function of adult
HSCs or HPCs [7, 11–13]. Recently, de Pater et al. dem-
onstrated that GATA2-deficient hemogenic endothelium
(HE) failed to generate long-term repopulating HSCs due
to the impairment of endothelial to hematopoietic transi-
tion (EHT) [14]. Mechanistically, GATA2 might regulate
HPCs through direct activation of other critical factors.le is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
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and Scl/Tal1 formed a regulatory circuit to regulate early
hematopoietic development in the mouse model [1].
Besides HSCs or HPCs, GATA2 also regulates hemato-
poietic lineage specification. For example, overexpres-
sion of GATA2 in primary erythroid progenitor cells
promoted megakaryocyte differentiation while inhibit-
ing erythrocyte differentiation [15]. Adult bone marrow
from GATA2 heterozygous mice (GATA2+/−) exhibited
reduced function of granulocyte-macrophage progeni-
tors (GMPs) [16]. The diverse roles of GATA2 in differ-
ent hematopoietic lineages indicate that its function is
largely cell context-dependent [17, 18]. Given that most
of the data available now on how GATA2 regulates
hematopoiesis are obtained from the murine system, its
roles in human background remain elusive and require
further investigation.
Human embryonic stem cells (hESCs) are capable of
hematopoietic differentiation in vitro and thus could
serve as a valuable model for investigating early human
hematopoiesis. They could efficiently differentiate into
HPCs as well as different hematopoietic lineages,
through either co-culturing with stromal cells or embry-
oid body (EB) formation in the presence of specific cyto-
kines [19, 20]. The hESC-derived HPCs exhibited typical
phenotype of blood progenitors, including expressing
surface markers as well as forming different blood
lineage colonies (colony-forming cells, CFCs). Moreover,
most studies to date support that the in vitro blood dif-
ferentiation of hESCs was a controlled sequential
process starting from the early embryonic mesoderm,
via HE and HPCs to mature blood cells, recapitulating
hematopoietic development in vivo [21, 22]. Therefore,
it could serve as a good system to examine the role of
GATA2 during early human hematopoiesis.
In this report, through gene targeting, we generated
GATA2−/− human ESCs and analyzed their hematopoietic
differentiation potential. Through examining surface
markers that were previously identified in hESC-derived
HPCs (CD34+CD43+) [23, 24], we found that GATA2−/−
hESCs generated much less HPCs both in the OP9 co-
culturing system and a stromal-free medium that could
drive blood differentiation. However, GATA2−/− hESCs
retained the potential to produce the major subtype blood
lineages, such as erythroblasts and macrophages. In con-
trast, we observed a complete defect of GATA2−/− hESCs
in generating granulocytes in OP9-driven blood differenti-
ation. Mechanistically, we identified that the granulocyte
defect was partially due to the downregulation of SPI1, a
critical transcription factor known for myeloid and
lymphocyte development in the mouse model. Enforced
expression of SPI1 rescued the production of granulocytes
of GATA2−/− hESCs in co-culturing with OP9. Interest-
ingly, GATA2−/− hESCs restored the potential when co-culturing with OP9 expressing DL1, the Notch signaling
ligand. Thus, our findings revealed the critical roles of
GATA2 in EHT and granulocyte development in human-
modeled hematopoiesis.
Results
Generation of GATA2−/− human ESCs
Gene targeting in hESCs could be significantly improved
with the aid of specifically designed nucleases such as zinc
finger nucleases (ZFNs) or transcription activator-like ef-
fector nucleases (TALENs) [25–27]. In order to generate
GATA2 null human ES cells, we firstly constructed a tar-
geting vector in which a PGK-driven neomycin resistance
cassette inserted into exon 3 of the GATA2 gene (Fig. 1a).
To facilitate gene targeting, we designed a pair of TALENs
specifically recognized and cut the targeting site of the
human GATA2 gene. Based on a reporter assay for analyz-
ing the efficiency of TALENs [28], we showed that the
TALENs were highly specific and efficient (Additional
file 1: Figure S1A-C). Then, we introduced the linear-
ized targeting vector together with the TALENs into H1
hESCs through electroporation and selected the posi-
tive clones using neomycin. After selection, drug-
resistant colonies were manually picked for further ex-
pansion and screening by genomic PCR and Southern
blot. Eventually, we successfully expanded an H1 hESC
clone with homozygous disruption of GATA2 alleles
(GATA2−/−) (Fig. 1b–d). The disruption could result in
the inability of these cells to generate functional
GATA2 protein even though an aberrant mRNA might
be generated (Additional file 1: Figure S1D). GATA2−/−
H1 hESCs maintained under undifferentiated condition
kept a normal karyotype and exhibited similar charac-
teristics to the wild-type (WT) counterpart regarding
surface marker expression, global gene expression pro-
file, as well as teratoma formation (Fig. 1e–h). Furthermore,
GATA2−/− H1 could form typical EBs with upregulation of
markers for three early embryonic germ layers during
random differentiation (Additional file 1: Figure S2). In
summary, GATA2 disruption did not generate obvious
alterations in hESCs under conditions for hESC self-
renewal and random differentiation.
GATA2−/− hESCs generate reduced HPCs due to EHT
defect
Since GATA2 has been known to be a master regulator
for hematopoiesis, we sought to analyze the hematopoietic
potential of GATA2−/− hESCs. In a stromal-free defined
condition that could drive blood differentiation, we
showed that in contrast to WT hESCs, GATA2−/− hESCs
generated a few HPCs (CD34+CD43+) and blood colony-
forming units (CFUs) (Additional file 1: Figure S3). How-
ever, when co-culturing with OP9 stromal cells, GATA2−/−
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Fig. 1 Generation of GATA2−/− human ESCs. a Schematic overview of gene targeting strategy. For GATA2 knockout, a PGK promoter-neomycin
cassette replaces exon 3 of the GATA2 locus. BglII sites, TALEN sites, primers (P1, P2), and probes (probe 1, probe 2) used for genomic PCR and
Southern blot are indicated. b Genomic PCR for GATA2 targeting. PCR product by indicated primers is 0.76 kb from WT H1 cells and 2.44 kb from
H1-GATA2−/−. c, d Southern blot analysis of GATA2 targeted H1 cells. The genomic DNAs were digested by BglII and detected by indicated probes.
One single band detected by probe 1 indicates that there was no random integration of drug cassette. e FACS analysis of the expression of
OCT4, SSEA-4, TRA-1-60, and TRA-1-81 in H1 or H1-GATA2−/− cells. In these and other flow cytometry diagrams, the black line stands for the control
and the red line for the experimental plot unless otherwise indicated. f Teratoma formation of H1 or H1-GATA2−/− cells. g Paired Pearson
correlation analysis of global gene expression between WT and GATA2−/− H1 cells. R Pearson correlation coefficient, TPM transcripts per million.
h Karyotype analysis of the H1-GATA2−/− cell line








































































































































































































































































































































































































































































































Fig. 2 (See legend on next page.)
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Fig. 2 Hematopoietic differentiation of the H1-GATA2−/− ES cell line. a CFUs of H1 or H1-GATA2−/− derived CD34+ cells. H1 or H1-GATA2−/− cells
were co-cultured with OP9 cells for 9 days. The CD34+ HPCs were isolated by FACS for CFU generation. Error bars represent mean + SEM of the
mean of samples from nine independent experiments. b-d Time course analysis of blood differentiation of H1 and H1-GATA2−/− cells upon
co-culturing with OP9. The expression of surface markers CD34, CD43, and CD31 on H1 or H1-GATA2−/− cells co-cultured with OP9 for the
indicated time was analyzed by FACS (left and middle panels). The right panels are box plots from ten independent experiments on the
percentage of indicated populations on day 8 of OP9 co-culturing. Asterisks indicate statistical significance determined by t test: ***p < 0.001.
e Time course analysis of the expression of indicated genes of H1 and H1-GATA2−/− cells upon co-culturing with OP9. The gene expression was
analyzed by qRT-PCR by using GAPDH as an internal reference. f HPCs with CD34+CD31+CD43+ were developed from CD34+CD31+CD43− HEs.
CD34+CD31+CD43− populations were sorted out at day 8 of differentiation and replated on OP9 for one additional day and analyzed by FACS.
g FACS analysis of CD114 and KDR on HEs from H1 or H1-GATA2−/−. h H1 or H1-GATA2−/− derived HEs produced endothelial cells. Left:
Morphology of endothelial cells; middle: immunostaining of CD31 on endothelial cells; right: capillary structure formation by endothelial cells
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model that mouse ES cells lacking Gata2 could gener-
ate certain blood lineages, such as erythrocytes [10].
We confirmed that the GATA2−/− hESCs failed to ex-
press full-length GATA2 mRNAs during the whole
process of blood differentiation driven by OP9 co-
culture (Fig. 2e and Additional file 1: Figure S1D).
Then, we attempted to analyze this process in detail.
Upon OP9 co-culture, the HPCs with CFU potential
were believed to develop through the EHT process
from HEs, the endothelial cells with hematopoietic po-
tential [21, 22, 29–35]. Through further analyzing the
surface markers at different differentiation stages dur-
ing OP9 co-culture, we showed that GATA2−/− hESCs
exhibited little difference in the generation of CD34
+CD31+ HEs compared with WT hESCs, but signifi-
cant reduction in the production of CD34+CD43+
HPCs (Fig. 2b–d). These data indicated that GATA2
was critical for EHT to generate HPCs but not essen-
tial for HE determination. Consistently, the transcrip-
tion factors (TFs) critical for HE determination such
as RUNX1 and SCL/TAL1 [30] were successfully acti-
vated in GATA2−/− hESCs, albeit a little lower than in
WT hESCs (Fig. 2e, Additional file 1: Figure S4).
To further analyze the function of HEs from GATA2−/−
hESCs, we sorted out the CD34+CD31+CD43− HEs at day
8 of OP9 co-culture. Upon replating them onto OP9 cells
for further hematopoietic differentiation, HEs from
GATA2−/− hESCs produced much less CD43+ HPCs com-
pared with WT hESCs (Fig. 2f). Nevertheless, the HEs de-
rived from both WT and GATA2−/− hESCs expressed
typical endothelium markers such as KDR and CD144
(VE-Cadherin) (Fig. 2g). In addition, to explore their
endothelial potential, we re-cultured the sorted HEs in
endothelial growth medium onto a Matrigel-coated
plate. In this condition, GATA2−/− HEs underwent fur-
ther endothelial differentiation that displayed a typical
endothelial phenotype and formed vascular tubes,
which are comparable to WT HEs (Fig. 2h). In general,
our data showed that GATA2 null hESCs could develop
into functional HE lineages, but undergo deficient EHT
to produce HPCs.Characterization of hematopoietic potential of GATA2
null HPCs
As shown in Fig. 2a, although we could easily detect the
major colony-forming cell (CFC) types including eryth-
roid (CFC-E or BFU) and myeloid (granulocytes and
macrophages, CFU-Mix) from WT hESCs upon co-
culturing with OP9, we only observed erythroid and
macrophage CFCs from GATA2−/− CD34+ cells. We
never detected granulocytes (CFU-G) from GATA2−/−
CD34+ cells. Consistent with previous findings, we
showed that the potential cells were restricted within the
population of CD34+CD43+ (Fig. 3a) [23]. These data in-
dicated that GATA2 might particularly target and regu-
late granulocyte specification in human ESC-based
hematopoiesis.
We then further performed comprehensive charac-
terization of all myeloid lineages generated from GATA2−/−
hESCs/OP9 co-culture. Regarding in vivo embryonic
hematopoiesis, two distinct hematopoietic programs, the
primitive hematopoiesis and definitive hematopoiesis, have
been demonstrated to produce different subtype blood line-
ages [36]. The primitive hematopoiesis occurred early and
mainly produced primitive erythroblasts and macrophages,
while the definitive hematopoiesis was associated with de-
finitive erythroid expressing adult beta-globin and pan-
myeloid precursors [24]. Both distinct programs have been
detected during in vitro hESCs/OP9 co-culturing, but it re-
mains largely challenging to precisely define and separate
these two stages [37]. In our system, we could easily de-
tect the erythroid precursors from GATA2−/− hESCs/
OP9 co-culture, characterized by forming E-CFUs or
even BFUs (Fig. 3c) with expression of CD235a and
CD71, the well-established markers for in vitro-gener-
ated erythroid cells [33] (Fig. 3b). Furthermore, we
could detect the expression of both adult globin (HBB)
and embryonic globins (HBE and HBG) in erythrocytes
from GATA2−/− hESCs/OP9 (Fig. 3c). Consistently,
GATA1, the critical factor known for erythroid specifi-
cation, was successfully activated and detected in
GATA2−/− erythrocytes (Fig. 3d).
In contrast, myeloid lineages from GATA2−/− hESCs


























































































































































































Fig. 3 (See legend on next page.)
Huang et al. Cell Regeneration  (2015) 4:4 Page 6 of 15
(See figure on previous page.)
Fig. 3 Characterization of subtype blood lineages from H1 or H1-GATA2−/− derived HPCs. a CFU potential cells from H1 or H1-GATA2−/− were
restricted within CD34+CD43+ subpopulations. EC endothelial cells, MC mesenchymal cells. b Characterization of erythrocytes from H1 or H1-
GATA2−/−. From left to right: phase-contrast photographs of BFU and CFU-E, FACS analysis of CD235a and CD71a expression on H1 and H1-
GATA2−/− derived erythrocytes, and cytospin of H1 and H1-GATA2−/− derived erythrocytes. c Globin analysis of erythrocytes by RT-qPCR. The
results showed the mean + SEM of one single experiment with three replicates, representative of three independent experiments. d Analysis
of expression of GATA1, GATA2, and GATA3 in H1 or H1-GATA2−/− derived erythrocytes. The results showed the mean + SEM of one single
experiment with three replicates, representative of three independent experiments. e Characterization of myeloid cells from H1 or H1-GATA2−/−. Left:
morphologies of indicated CFU colonies; middle: FACS analysis of indicated markers; right: cytospin photographs of indicated colonies. f FACS
analysis of CD86 and CD14 expression in H1 and H1-GATA2−/− derived myeloid CFU. E erythrocyte, G granulocyte, M macrophage, GM G and
M, Mix G, E, and M
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lineages such as macrophage (M-CFCs), granulocyte (G-
CFCs), and pan-myeloid CFCs (CFU-Mix) were ob-
served from WT hESCs, we only observed mononuclear
cells from GATA2−/− hESCs, which displayed macro-
phage morphology under a microscope (Fig. 3e). To fur-
ther confirm the identity of mononuclear cells from
GATA2−/− HPCs, we performed fluorescence-activated
cell sorting (FACS) analysis of these cells with specific
surface markers. For these surface markers, macrophages
highly express both CD11b and CD14 while granulo-
cytes express high CD11b but low CD14; thus, they
could be used to discriminate these two lineages as re-
ported by Rafii et al. [33]. Consistently, we showed that
GATA2−/− hESC-derived myeloid cells displayed high ex-
pression of both CD11b and CD14, demonstrating that
these cells were macrophages, but not granulocytes
(Fig. 3e). In another literature, Choi et al. reported that
CD14 was expressed in both granulocytic and monocytic
cells generated in vitro [38]. Thus, we also examined an
additional surface marker to separate these two popula-
tions, for example, CD86, which is highly expressed in
monocytes/macrophages, but lowly expressed in granu-
locytes [39]. We found that the GATA2−/− hESC-derived
myeloid cells exclusively expressed high level of CD86
(Fig. 3f ), further demonstrating that GATA2−/− hESCs
produced macrophages (M-CFCs), not granulocytes (G-
CFCs). Further, Giemsa staining confirmed the morph-
ology for macrophage, but not granulocyte for these
monocytes (Fig. 3e). Overall, these data revealed an es-
sential role of GATA2 in regulating granulocyte gener-
ation during human ESC-modeled hematopoiesis.
SPI1 was responsible for the HPC and granulocyte defects
of GATA2−/− hESCs
To probe the underlying mechanisms of EHT and gran-
ulocyte defects of GATA2−/− hESCs, we performed
RNA-Seq analysis at different hematopoietic differenti-
ation stages. Through hierarchical cluster analysis of the
whole genome expression data, we showed that the sam-
ples at the same differentiation stage were highly corre-
lated, regardless of GATA2 status (Fig. 4a). Genes
upregulated in HEs and HPCs were enriched for thebiological function in blood and vessel development, in-
dicating that GATA2 deficiency did not abolish the gen-
eral blood lineage specification. Indeed, further
comparison of HEs or HPCs from GATA2−/− hESCs
with their counterparts from WT hESCs revealed much
less difference on the global expression profile (Fig. 4b).
In order to figure out the reason for GATA2−/− HPC fail-
ure in the generation of granulocytes, we examined num-
bers of genes that were known as critical hematopoietic
regulators, particularly those downregulated in H1-
GATA2−/− derived HE and/or HPC (Fig. 4c). Even though
most of these regulators exhibited less difference be-
tween GATA2−/− and WT cells, we did find some differ-
entially expressed genes, for example, SPI1. SPI1 is a
transcription factor that is highly expressed in myeloid
and known to be critical for proper development and
function of these lineages [40]. Further, through qRT-
PCR analysis, we confirmed that GATA2−/− hESCs
failed to activate SPI1 upon co-culture with OP9
(Fig. 4c). These data suggested that SPI1 might be the
downstream target for GATA2 to regulate EHT and
granulocyte development.
Forced expression of SPI1 rescued HPC and granulocyte
defects in GATA2−/− hESCs
A mouse embryo with homozygous mutation of SPI1
died at later gestation stage with a complete loss of B
cells, T cells, and macrophages, demonstrating the essen-
tial role of SPI1 in the proper development of such line-
ages [41], and SPI1 is one of the four genes used by
Sandler et al. to induce hematopoietic MPPs from
HUVECs [42]. However, the role of SPI1 in granulocyte
development has been conflicting and not yet well docu-
mented. Therefore, we sought to examine whether acti-
vation of SPI1 could rescue the granulocyte defect of
GATA2−/− hESCs. To this end, we constructed an indu-
cible vector expressing SPI1 in a lentiviral backbone [43]
and introduced it into GATA2−/− hESCs (Fig. 5a), which
could be expressed with Dox addition (Additional file 1:
Figure S5). Because SPI1 only started to express at day 6
of differentiation in WT hESCs/OP9 co-culturing
(Fig. 4d), we just induced the expression of SPI1 starting
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Fig. 4 (See legend on next page.)
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Fig. 4 Global gene expression analyses of H1 or H1-GATA2−/− derived HPC and HE. a Hierarchical clustering analysis of RNA-Seq data for indicated
samples. Genes with TPMs above 1 and at least threefold change compared with each of any other sample were selected for the analysis. Gene
expression values were normalized by Z score and clustered using Clustergram software. The enriched biological functions of the indicated gene
group were analyzed by Gene Ontology (GO). HPC: CD34+CD43+ cells sorted at day 9 of co-culture; HE: CD34+CD31+CD43− cells sorted at day 8
of co-culture. b Paired Pearson correlation analysis of H1 and H1-GATA2−/− derived HEs (left) or HPCs (right). R Pearson correlation coefficient, TPM
transcripts per million. Selected genes (red) are highlighted. c Heat map of selected genes based on TPM value of indicated samples. d Time
course analysis of SPI1 expression during the OP9 co-culture by qRT-PCR. Error bars represent SEM of the mean of one single experiment with
three replicates, representative of three independent experiments
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duction of SPI1, we showed that CD34+CD43+ HPCs
were significantly restored in GATA2−/− hESCs/OP9 co-
culture (Fig. 5c). The granulocyte potential cells (G-
CFC) did re-appear in GATA2−/− hESCs/OP9 with
forced expression of SPI1 (Fig. 5d). However, consistent
with the previous finding that SPI1 could antagonize
with GATA1 to suppress erythropoiesis [44], we ob-
served a lower level of E-CFCs in GATA2−/− hESCs/OP9
with forced expression of SPI1 (Fig. 5d). Nonetheless,
the granulocytes re-established by SPI1 exhibited typical
morphology and surface marker expression compared
with those from WT hESCs (Fig. 5e–g). In summary, we
demonstrated that SPI1 was the target of GATA2 to en-
sure normal development of HPCs and granulocytes in
human ESC-modeled hematopoiesis, thus highlighting a
precise and specific role of GATA2 and SPI1 in the regu-
lation of EHT and granulocyte generation.
GATA2−/− hESCs partially restored the granulocyte
potential in the presence of Notch signaling
It has been shown that Notch signaling could inhibit
myelopoiesis on normal stem cells and uncommitted
hematopoietic progenitors. This inhibition largely
depended on the normal function of GATA2 and could
be rescued after GATA2 knockout [45]. However, it
remained elusive whether granulocyte commitment
could be restored after GATA2 knockout. Therefore, we
seeded WT or GATA2−/− hESC-derived CD34+ HPCs
directly onto wild-type OP9 or OP9 expressing DL1
(OP9-DL1), the Notch signaling ligand for further
myeloid differentiation with addition of cytokines [46]
(Fig. 6a). As shown in Fig. 6b, the total number of
CD11b+ myeloid cells generated from WT hESCs was
significantly reduced upon co-culturing with OP9-DL1
compared with OP9, indicating that Notch signaling in-
deed inhibits myelopoiesis in human cells. However, the
Notch-mediated inhibition of myelopoiesis was not obvi-
ous on GATA2−/ hESC-derived CD34+ HPCs (Fig. 6b,
upper panel), demonstrating that GATA2 was the critical
downstream factor for Notch signaling to inhibit myelo-
poiesis. Furthermore, we showed that the CD11b+CD14−
granulocytes from GATA2−/− hESCs were significantly
restored in the presence of Notch signaling (Fig. 6b,lower panel). Additional markers, such as CD86, also
confirmed the generation of granulocytes of GATA2−/−
hESCs on OP9-DL1 (Fig. 6c). These findings demon-
strate that the granulocyte potential of GATA2−/− hESCs
could be restored in the presence of Notch signaling.
Discussion
Currently, studies on hematopoiesis by gene knockout
approach have been limited to model organisms, such as
zebra fish and mice, while studies on the genetic deter-
minants of human hematopoiesis have been confined to
overexpression and knockdown in human pluripotent
stem cells. In this report, we proved that human ESCs
combined with gene knockout could be utilized to inves-
tigate early human hematopoiesis by demonstrating
hematopoietic defects generated through deletion of a
key hematopoietic transcription factor GATA2 from hu-
man ES cell line by TALEN.
The GATA family contains a series of factors that are
evolutionally conserved and essential for proper devel-
opment in mammals. Among them, GATA1, GATA2,
and GATA3 express and function predominantly in
hematopoietic lineage cells [13, 47]. These factors exhib-
ited spatial and temporal expression patterns among dif-
ferent hematopoietic lineages. For example, GATA2
expression displayed broad distribution but with a prom-
inently high level in early hematopoietic progenitors
[12]. The function of GATA factors have been exten-
sively examined in the mouse model through various
in vivo experimental approaches. It becomes more and
more clear that GATA2 is required for the genesis and/
or function of HSCs. However, the function of GATA
factors in human hematopoiesis has not been clearly elu-
cidated due to the limitation of embryonic materials.
Here, taking the in vitro hematopoietic differentiation of
human ESCs as a model, we were able to analyze the
function of GATA2 in human background. Aided by
TALENs to enhance genome editing, we generated hu-
man ESCs with homozygous mutation on GATA2
(GATA2−/− hESCs). GATA2−/− hESCs behaved similarly
to their wild-type counterparts.
In contrast, regarding hematopoietic differentiation,
we observed that GATA2−/− hESCs generated much less
HPCs marked by CD34+CD43+ based on the OP9 co-
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Fig. 5 (See legend on next page.)
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Fig. 5 Forced expression of SPI1 in H1-GATA2−/− restores the generation of granulocytes upon OP9 co-culture. a, b Diagram of the strategy of
SPI1 rescue experiments. SPI1 linked with a puromycin resistance gene by T2A sequence was controlled by a Dox-inducible promoter in lentiviral-
based vectors for Dox-inducible expression of SPI1. The expression of SPI1 was not induced during later CFU assay. c Effects of enforced
expression of SPI1 on generation of in CD34+ (left) and CD34+CD43+ (right) HPCs in H1-GATA2−/−. Results are presented as mean + SEM of five
independent experiments and normalized to H1 group. The data on CD34+ cells generation (left) were set as 1 for comparison. The data from five
independent experiments were shown as box plot. Asterisks indicate statistical significance determined by t test: *p < 0.05, **p < 0.01 and ***p < 0.001.
d Enforced expression of SPI1 in H1-GATA2−/− regenerate G-CFUs. The error bars indicate mean + SEM of three independent experiments.
e Morphology of CFU-G regenerated by SPI1 expression; bottom: cytospin of CFU-G. f, g FACS analysis of indicated markers in SPI1 regenerated CFU-M

































































































Fig. 6 H1-GATA2−/− cells restored the potential of granulocyte on OP9-DL1. a Diagram of the strategy of the experiments. H1 or H1-GATA2−/− ES
cells were co-cultured with OP9 for 9 days, then the CD34+ HPCs were harvested and seeded onto OP9 or OP9-DL1 cells for myeloid differentiation.
b CD11b and CD14 expression at day 12 of OP9/OP9-DL1-mediated myeloid differentiation were analyzed by FACS. Percentage of total CD11b+
myeloid cells or CD11b+CD14− granulocytes were shown at the left. The right bar charts represent the statistic results of relative generation of CD11b+
cells of indicated test (up) and the generation of CD11b+CD14− cells (down). The data of H1 and H1-GATA2−/− from the OP9 co-culture for CD11b+
cell generation were set as 1 for comparison. Results indicate mean + SEM of three independent experiments. Asterisks represent statistical
significance determined by t test: *p < 0.05 and **p < 0.01. c FACS analysis of CD86 and CD14 expression in day 12 of OP9/OP9-DL1-mediated
myeloid differentiation
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Huang et al. Cell Regeneration  (2015) 4:4 Page 12 of 15culture system, but retained the potential to differentiate
into major types of hematopoietic lineages, such as
erythrocyte and macrophage. Surprisingly, we failed to
observed granulocyte differentiation from GATA2−/−
hESCs. This is very different from previous reports. In the
mouse model, Tsai and de Pater et al. reported that
Gata2−/− mouse ESCs are capable of producing multi-
potential CFCs including granulocytes albeit in a much
smaller number compared to wild-type ESCs [10, 14],
and Gao et al. documented the abolished CFC potential
of Gata2−/− AGM cells. Our findings indicated that the
function of GATA2 would be very crucial for granulocyte
development in human ESC-modeled hematopoiesis
(Additional file 1: Figure S5). Meanwhile, it is worthy to
note that the HPCs from GATA2−/− hESCs failed to
generate any blood CFCs in the stromal-free system
(Additional file 1: Figure S3), indicating that OP9 might
provide additional factors or proper niche to allow CFC
formation for GATA2−/− HPCs. In addition, the pres-
ence of Notch signaling in OP9 stromal cells restored
the granulocyte potential of GATA2−/− ESCs. This find-
ing is consistent with a previous report [45] and sug-
gests that the effect of Notch signaling in GMP cells
requires GATA2 and GATA2 is the downstream of
Notch signaling to inhibit HPC commitment to myeloid
lineage, and further highlights the important role of the
interaction between the extracellular environment and
intracellular gene regulation in blood cell development.
GATA2 was also found to play a role in vascular integ-
rity. Mammoto et al. reported that knockdown of
GATA2 in endothelial cells impaired vascular formation
of human endothelial cells both in vitro and in vivo [48].
Also, Kazenwadel et al. reported that GATA2 knock-
down in primary lymphatic endothelial cells abolished
the lymphatic endothelial cell marker expression of
FOXC2, PROX1, ITGA9, VEGFR3, and ANGPT2 [49].
However, Tsai et al. found that GATA2−/− embryos
showed apparently normal endothelial cells, vitelline vas-
culature, and heart on E9.5 [10]. Consistent with the re-
port of Tsai et al., we found that the endothelium and
vascular formation potential of GATA2−/− hESCs were
normal as demonstrated by capillary structure formation
and we observed no general defects in the lymphatic
endothelial cell marker expression after GATA2 muta-
tion. This may be due to a complementary mechanism
which compensates for the deletion of GATA2.
At the molecular level, several factors have been re-
ported to be direct downstream targets of GATA2 at
the HSC stage. For example, SCL/Tal1, a critical factor
that controls survival of HPCs at early hematopoiesis,
seems to be directly activated and maintained by
GATA2 in mouse models [1]. Runx1, another important
factor for normal hematopoiesis, was also directly tar-
geted and maintained by Gata2 in mouse HPCs [50].However, these factors as well as some well-known
hematopoietic factors were successfully activated in the
absence of GATA2 upon hematopoietic differentiation
of human ESCs in our system (Fig. 4c), which might ex-
plain why most blood lineages could be generated.
However, SPI1, a critical gene, which has been reported
to be involved in myeloid development, was signifi-
cantly downregulated in GATA2−/− HE and HPCs. Al-
though the partial rescue effect of SPI1 may be due to
the overdose effect of forced SPI1 expression, it may
also imply that other candidate targets of GATA2 con-
tribute to EHT and/or granulocyte development yet not
carefully examined currently.
GATA2−/− hESCs failed to express SPI1 upon in vitro
hematopoiesis through co-culturing with OP9, and
GATA2 has been reported to directly target and activate
the SPI1 locus in mouse HPCs through two conserved
regions [51]. GATA2 has been reported to be involved in
EHT [8, 14, 52], whereas the role of SPI1 in EHT has
not been well documented. Until very recently, Adam
et al. reported that Spi1 was upregulated during the
EHT process [53], and in another milestone study,
Sandler et al. reported reprogramming of human endo-
thelial cells to transplantable hematopoietic progenitor
cells by FOSB, GFI1, RUNX1, and SPI1 induction [42].
These studies combined with our report proved that
SPI1 would potentially serve as an important regulator
in EHT. Nevertheless, it is still worthy to note that
Gata2 might be with specific functions in SPI1 regula-
tion in different cell types. For instance, Gata2 could
bind to the Cebpa promoter, blocking Spi1 and Runx1
binding, and so prevents Cebpa gene activation for the
maintenance of cellular identity of mast cells [54].
Previous studies on the role of SPI1 in granulopoiesis
have been conflictive in some degree. Spi1 has been
proved to be crucial for HSC maintenance and myeloid
differentiation [55], and Spi1 mutant embryos exhibited
multilineage defects including the impairment of granu-
locytes [56], while other studies reported that Spi1−/−
granulocyte-monocyte progenitors (GMP) can differenti-
ate into granulocytic precursors but with further matur-
ation impairment [57] and elimination of Spi1 in GMP
in adult mice showed disturbed hematopoiesis with
excess granulocyte production [58]. These studies indi-
cated specific roles of SPI1 at different stages of granulo-
cyte development. They implied that dysfunction of SPI1
impairs HSC generation and its commitment to down-
stream lineages including granulocyte, while SPI1 is not
essential for the differentiation of GMP to granulocyte.
In our study, we showed that SPI1 could rescue the
HPC generation of GATA2−/− hESCs and the restored
HPC is with granulocyte potential. These results con-
firmed the role of SPI1 in HPC generation and its differ-
entiation to granulocyte in mice and further highlight its
Huang et al. Cell Regeneration  (2015) 4:4 Page 13 of 15conserved role in regulating myeloid development during
hematopoiesis (Additional file 1: Figure S6).
Conclusion
In conclusion, we reported the first study of human
hematopoiesis through gene knockout and illustrated
the roles of GATA2 and SPI1 in EHT and granulocyte
generation in early human hematopoiesis. Particularly,
we revealed the impact of interaction between Notch
signaling and GATA2 on granulocyte development.
Methods
Targeting strategy
GATA2 knockout TALENs were designed as described
[25, 26], and their sequences and targeting site were il-
lustrated in Additional file 1: Figure S1. For donor con-
struction, left and right homology arms were cloned
from genomic DNA of the H1 cell line. A loxP-flanked
PGK-neomycin cassette was further inserted between
two homology arms in the vector pUC57. The vector is
linearized by EcoRI before targeting. For targeting, 1.5 ×
106 H1 cells were electroporated with 1 μg of donor
DNA and 2.5 μg of each TALEN plasmid. Then, the cells
were seeded on a Matrigel-coated six-well plate in the
presence of Y-27632 (10 μM, Sigma). After 2 or 3 days,
positive clones were selected by G418 (100 μg/ml,
Sigma). Further verifications were carried out by gen-
omic PCR and Southern blot. All primers referred are
listed in Additional file 1: Table S1.
Hematopoietic colony-forming assays
Hematopoietic colony-forming assays were performed in
35-mm culture dishes (Stem Cell Technologies, Inc.)
using 1 ml per dish of MethoCult™ H4435 enriched
medium (Stem Cell Technologies, Inc.) mixed with cells
of a certain number according to the manufacturer’s in-
structions. Colonies were counted on days 14–16 and
picked individually, washed in FACS buffer, and spun
onto slides with a cytospin apparatus (TXD-3). The cells
were then fixed and processed with Wright-Giemsa
staining.
FACS analysis and cell sorting
For GFP fluorescence analysis, cells were trypsinized and
suspended in FACS buffer (PBS with 2 % FBS (ExCell))
directly for detection by C6 (BD Accuri). For cell surface
antigen analysis, cells were stained with antibody cocktail
in FACS buffer at 4 °C for 15 to 30 min after trypsiniza-
tion. Specifically, to analyze day 9 subsets from co-culture,
cells were stained with CD43-FITC, CD31-PE, CD34-
PerCP-Cy5.5, and TRA-1-85-APC. To analyze and sort
HEs in day 8 and HPCs in day 9 of co-culture, CD34+ cells
were primarily isolated by MACS (Miltenyi Biotech) and
subsequently sorted using a FACSAria cell sorter (BDBiosciences) with cells stained by CD43-FITC, CD31-PE,
CD34-PerCP-Cy5.5, and TRA-1-85-APC. To analyze
endothelial markers expressed on HEs, cultured HEs were
stained by CD144-PE and KDR-PE, respectively. To
analyze colony-forming unit (CFU) surface makers, CFU-
E were stained with CD235a-PE and CD71a APC; CFU-
G/M/GM or myeloid cells derived from HPCs co-cultured
with OP9/OP9-DL1 were stained with CD11b-FITC,
CD33-PE, CD14-PerCP-Cy5.5, CD13-APC or CD11b-
FITC, CD86-PE, CD14-PerCP-Cy5.5; CFU-Mix cells were
stained with CD235a-PE, CD13-PerCP-Cy5.5, and
CD71a-APC. To analyze the surface maker expressed
on pluripotent stem cells, they were stained with no-
conjugated primary SSEA-4, TRA-1-60, and TRA-1-81
antibody, respectively, and further stained with species-
specific secondary antibodies conjugated to Alexa Fluor®
448 (Invitrogen). For intracellular antigen OCT4, PAX6,
and NESTIN analysis, cell fixation and permeabilization
were performed before antibody incubation and then cells
were stained with primary and secondary antibodies as
SSEA4. Particularly, for cell sorting, after staining with
antibodies, cells were further stained with DAPI excluding
dead cells; the purity of sorted fractions was more than
97 % as tested by FACS. All antibodies used for FACS ana-
lysis are listed in Additional file 1: Table S2.
Additional methods are listed in the Additional file 1.
Accession numbers
The RNA-Seq data are available in the Gene Expression
Omnibus database [accession number: GSE69797].
Additional file
Additional file 1: Supplemental information includes seven
supplemental figures, supplemental figure legends, two
supplemental tables, and the extended methods. (PDF 1270 kb)
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